AngioDynamics Introduces Morpheus™ Peripherally Inserted Central Catheter in the United StatesQueensbury, NY, April 14, 2004 – ANGIODYNAMICS, INC., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) today announced the introduction of the Morpheus™ peripherally inserted central catheter (PICC), a device used to obtain short- and long-term peripheral access to the central venous system for intravenous therapy and blood sampling. With today's announcement, the Morpheus PICC will be available for limited distribution within the United States.



PICCs are used in the administration of chemotherapy or other medications that require significant dilution in the blood to avoid blood vessel damage. The Morpheus PICC is constructed of Durathane™ material. This biocompatible and durable material offers increased stiffness for ease of placement while also providing patient comfort. The use of Durathane also helps simplify site care since the material can be cleaned with either iodine or alcohol. Typically, other PICCs must be cleaned with only one type of disinfectant as use of an improper cleaning agent can damage the catheter. Through AngioDynamics' patent pending Flextone™ technology, the Morpheus PICC is designed to provide a flexible catheter tip that helps minimize risk of vessel wall damage. The exposed catheter body is designed to be more durable, providing more resilience to chemical and cleaning agents and greater control over catheter placement.



Commenting for AngioDynamics, Don Geer, Director of Vascular Access said, “Knowing that the PICC line is a staple product of the Interventional Radiology field, we developed the Morpheus PICC with features designed to simplify placement and care of the catheter. This new and improved product represents AngioDynamics' ongoing dedication to innovation and to continually improving the tools of the Interventional Radiologist."



For additional information on the Morpheus PICC, contact Don Geer at 1-800-772-6446, ext. 167, Email: dgeer@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.



About AngioDynamics



AngioDynamics, Inc. (www.angiodynamics.com) manufactures a wide range of products, including angiographic, dialysis, PTA dilation, thrombolytic, image-guided vascular access, endovascular laser venous system, as well as abdominal infection drainage products. AngioDynamics' focus is on diagnostic and therapeutic products that enable interventional physicians to treat peripheral vascular diseases and other non-coronary diseases.



About E-Z-EM



E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA™ technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. For additional information, please contact Tom Johnson at 1-800-544-4624, ext. 3317, (E-mail: tjohnson@ezem.com) or visit our corporate web site at www.ezem.com



The statements made in this document contain certain forward looking statements that involve a number of risks and uncertainties. Words such as “expects”, “intends”, “anticipates”, “plans”, “believes”, “seeks”, “estimates,” or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the Morpheus™ PICC, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28, 2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.



Company Contacts:
AngioDynamics, Inc.
Lisa Donegan
(800) 772-6446 x370


www.angiodynamics.com

Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
(212) 838-3777

Bruce Voss (bvoss@lhai.com)
(310) 691-7100